Drug Information Association Logo

Posters at the EuroMeeting

Professional Posters

The Professional Poster session is an opportunity to present your research to a diverse group of professionals who attend the DIA EuroMeeting.


pdf Download Poster Guidelines [PDF]

Accepted Professional Poster Abstracts
A selected group of professional poster presenters will share their research results in various topics.
Visit the Exhibition Hall to view the Professional Posters.

View accepted professional posters that will be on display in the exhibition hall



Student Posters

The student poster programme is an opportunity for you to present your research results to a diverse group of scientific professionals who are actively involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and healthcare related issues. 

pdf Download Poster Guidelines [PDF]

View Accepted Student Poster Abstracts



Accepted Professional Poster Abstracts
A selected group of professional poster presenters will share their research results in various topics.
Visit the Exhibition Hall to view the Professional Posters.

P1: Amer Alanazi, Assistant Professor of Pharmaceutical Biotechnology, King Saud University, Saudi Arabia
Antifungal efficacy of Amphotericin B loaded plasma beads in treatment of Cryptococcus neoformans infection in mice

P2: Romuald Braun, e-consulting, Uanotau Ltd, Switzerland
Selection of an EDMS/RIM/QMS solution considering on-premises and off-premises approach.

P3: Zsuzsanna Csutor, Director of Pharmacovigilance Services, B&C Consulting, Switzerland
The Silver Lining of the Psmf - Flow Chart Displaying Business and user requirements

P4: Melissa Esteban Soto, Cornelius Schep, Safety Science Leader, F Hoffman-La Roche, Switzerland
Merging three aggregate safety reports into one Integrated Drug Safety Master File

P5: Brian Godman, Senior Researcher, Karolinska Institute, Sweden 
Essential to have new models to optimise the managed entry of new drugs in Europe

P6: Anna Kubik, Regulatory Manager, KCR.S.A, Poland
Registration of clinical trials in Serbia and Ukraine – submissions to CA and EC one day before European Union

P7: Sasha Lauks, Analyst, Quintiles Consulting, Inc, UK
The effect of Patient Reported Outcomes on Health Technology Assessment recommendations in Oncology in France, Germany and UK 

P8: Michael Marx, Associate Medical Director, Icon Clinical Research, Germany
Improvement of 24/7 Medical Emergency Coverage for both regional and global studies by using a single, global approach

P9: Deirdre McCarthy, Director, Integrated Post-Marketing and QPPV Services, Customer Safety Services, Quintiles Ireland, Ireland
Advances in the understanding of depression and the safety profile of novel therapeutic strategies

P10: Toshinori Murayama, Deputy Director and Associate Professor, Kyoto University Hospital, Japan
Kyoto University Hospital Institute for Advancement of Clinical and Translational Science (iACT), aiming at a worldwide ARO

P11: Darshan Patel, Associate Director Regulatory Affairs, Sunovion Pharmaceuticals Inc., USA
Comparison of Clinical Trial Application Approval Rates for Global, Placebo-Controlled Versus Comparator-Controlled Studies

P12: Krista Payne, Executive Director and Principal Scientific Consultant, Dara Stein, Senior Research Scientist United Biosource Corporation (UBC), Canada
Retrospective chart review studies and safety reporting requirements: issues and considerations

P13: Ludivine Pennaneach, Solution Specialist, Thomson Reuters, France
30 Years of the Hatch Waxman Act of 1984: Will three decades of growth in small molecule generics be followed by biosimilars?

P14: Richard Preston, Professor Clinical Medicine, Director, Clinical Pharmacology Research, University of Miami, USA
Effects of Nebivolol versus Metoprolol on Sodium Sensitivity and Renal Sodium Handling in Hypertensive Postmenopausal Women

P15: Badri Rengarajan, Senior Medical Director, Evidera, USA
Using Virtual Population Simulation to Identify Possible Areas of Cardiovascular Safety Concern

P16: Hege Roenning, Managing Director Norway, Lindeq, Norway
Reporting of serious undesirable effects (SUEs) in compliance with Regulation No 1223/2009

P17: Mikhail Samsonov, Chief Medical Officer, R-Pharm, Russian Federation
Use of web based automated workflows in pharmaceutical industry

P18: Thomas Schindler, Head Medical Writing, Boehringer Ingelheim Pharma GmbH., Germany
What represents good quality in a clinical study report?

P19: Soumick Sikdar, Senior Safety Scientist, Amal Sottou, Safety Physician, United Biosource Corporation (UBC), UK
The current challenges in dealing with adverse event reports from social media

P20: Ernst Singer, Professor of Pharmacology, Chairman Ethics Committee of the Medical University of Vienna, Austria
ECS - an open-source software solution satisfying all requirements of an EC office. The Vienna Experience.

P21: Tina Wang, Portfolio Manager HTA Programme, CIRS Centre for Innovation in Regulatory Science, UK
Availability of New Medicines – Characterising the factors influencing drug roll out to six mature markets

P22: Bernd Westhof, Senior Director Benefit Risk Management, Quintiles Gmbh., Germany
A strategic approach to portfolio Benefit Risk Assessments (BRAs)

P23: Manabu Yamamoto, Clinical Research Division, Japan Medical Association Centre for Clinical Trials, Japan
Investigator-Initiated Clinical Trials Outcomes and actions taken by JMACCT

P24: Alexis Pincon, Managing Director, Nour Zibian, Safety Scientist, United Biosource Corporation (UBC), Switzerland
A signal management adaptative model

Accepted Student Poster Abstracts

SP1: Ana Begic, Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia
Biomedical potential of Stevia - Stevia rebaudiana (Bert.) Bertoni

SP2: Charlotte Benoit, Samer Bounni, Université Claude Bernard Lyon 1, France
ACE-inhibitors for the prevention of sudden cardiac death: a meta-analysis of randomised
controlled trials


SP3: Pauline Blanchard, Vanessa Ville, Claude Bernard University, France, 
Incidence of hypersensitivity reactions (HSR) to oxaliplatin (OP), identification and meta-analysis of potential risk factors.

SP4: Jessica Bonnefoy Isabelle Delfour, Gwenaelle Denis, Eudipharm, France 
Designs for Phase I clinical trials in pediatrics. Comparison of methodologies to determine the efficacious dose.

SP5: Katarina Iric, Faculty of Pharmacy, Serbia 
Testing the impact of modified reformatsky reaction on the synthesis of 3,3-bis-(4-chlorophenyl)-3-hydroxypropionic acid.

SP6: Monica Luca, University of Medicine and Pharmacy Carol Davila Bucharest, Romania
Evaluation of the non-clinical action of alpha-lipoic acid on Vincristine- and Paclitaxel-induced neuropathic pain.

SP7: Alexia Malriq, Hospices Civil De Lyon, University of Lyon, France, 
Clinical Trial Data Sharing: Public access to clinical trials data on medicinal products is coming soon

SP8: Florence Margraff, Hospices Civil De Lyon, University of Lyon, France. 
Adverse drug reaction reporting by patients in fifty countries.

SP9: Monika Mironiuk, Medical University of Gdansk, Poland. 
Plasma non-targeted metabolic fingerprinting as a potential prognostic tool for drug-resistant hypertension.

SP10: Julie Mouchet, Lucile Penaud, Université Claude Bernard Lyon I, France
Is there a publication bias for studies assessing the benefit of fatty acids in attention deficit hyperactivity disorder?

SP11: Isabelle Rodrigues, University of Lisbon, Portugal 
Ibuprofen promotes age-related bradikinin but not the acethylcholine - induced rat ileal contractility.

SP12: Maidah Sheikh, University of Vienna, Austria
The organic anion transporting polypeptide OATP4A1 may be a target for immunomodulation in early colorectal cancer.

SP13: Indre Šveikauskaite, Lithuanian University of Health Sciences, Lithuania
Differences of lead and nickel ions effects on total protein and metallothioneins synthesis in mice liver.

SP14: Birce Didar Tut, Istanbul University, Turkey
Assessment of risk management approaches in orphan drugs.